![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CCDC151 |
Gene summary for CCDC151 |
![]() |
Gene information | Species | Human | Gene symbol | CCDC151 | Gene ID | 115948 |
Gene name | outer dynein arm docking complex subunit 3 | |
Gene Alias | CCDC151 | |
Cytomap | 19p13.2 | |
Gene Type | protein-coding | GO ID | GO:0000226 | UniProtAcc | A5D8V7 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
115948 | CCDC151 | PTC04 | Human | Thyroid | PTC | 1.15e-03 | 9.13e-02 | 0.1927 |
115948 | CCDC151 | PTC07 | Human | Thyroid | PTC | 8.46e-09 | 1.65e-01 | 0.2044 |
115948 | CCDC151 | ATC13 | Human | Thyroid | ATC | 8.17e-31 | 6.12e-01 | 0.34 |
115948 | CCDC151 | ATC5 | Human | Thyroid | ATC | 4.60e-30 | 6.55e-01 | 0.34 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ![]() | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CCDC151 | SNV | Missense_Mutation | c.1507N>A | p.Val503Met | p.V503M | A5D8V7 | protein_coding | deleterious(0.02) | probably_damaging(0.973) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
CCDC151 | SNV | Missense_Mutation | c.859G>C | p.Glu287Gln | p.E287Q | A5D8V7 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-C8-A275-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
CCDC151 | SNV | Missense_Mutation | c.733N>C | p.Glu245Gln | p.E245Q | A5D8V7 | protein_coding | tolerated(0.39) | benign(0.066) | TCGA-EW-A1OZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Targeted Molecular therapy | trastuzumab | SD | |
CCDC151 | insertion | Frame_Shift_Ins | novel | c.1770_1771insA | p.Arg591ThrfsTer10 | p.R591Tfs*10 | A5D8V7 | protein_coding | TCGA-AQ-A04J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
CCDC151 | insertion | Frame_Shift_Ins | novel | c.998_999insGGTGGGGGTGGAGTGGGGTGGTAAAGGGAAGGGGAGC | p.Asp333GlufsTer49 | p.D333Efs*49 | A5D8V7 | protein_coding | TCGA-AR-A0TY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | PD | ||
CCDC151 | SNV | Missense_Mutation | rs368057071 | c.659N>T | p.Ala220Val | p.A220V | A5D8V7 | protein_coding | tolerated(0.25) | possibly_damaging(0.736) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
CCDC151 | SNV | Missense_Mutation | novel | c.1678G>A | p.Glu560Lys | p.E560K | A5D8V7 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
CCDC151 | SNV | Missense_Mutation | rs759215057 | c.167N>A | p.Gly56Glu | p.G56E | A5D8V7 | protein_coding | deleterious(0.05) | benign(0.343) | TCGA-IR-A3LI-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
CCDC151 | SNV | Missense_Mutation | c.1763A>G | p.Lys588Arg | p.K588R | A5D8V7 | protein_coding | deleterious(0.04) | benign(0.017) | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
CCDC151 | SNV | Missense_Mutation | novel | c.1243G>T | p.Asp415Tyr | p.D415Y | A5D8V7 | protein_coding | deleterious(0.01) | benign(0.347) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |